Trade Cardiff Oncology, Inc. - CRDF CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0400 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.875 |
| Open | 2.83 |
| 1-Year Change | -31.72% |
| Day's Range | 2.785 - 2.865 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 2.8750 | -0.0550 | -1.88% | 2.9300 | 2.9700 | 2.7950 |
| Apr 23, 2025 | 2.9050 | -0.2750 | -8.65% | 3.1800 | 3.2600 | 2.8950 |
| Apr 22, 2025 | 3.0250 | 0.2050 | 7.27% | 2.8200 | 3.0600 | 2.8200 |
| Apr 21, 2025 | 2.8050 | -0.0050 | -0.18% | 2.8100 | 2.8900 | 2.7500 |
| Apr 17, 2025 | 2.8500 | 0.0900 | 3.26% | 2.7600 | 2.8650 | 2.7150 |
| Apr 16, 2025 | 2.7850 | -0.2050 | -6.86% | 2.9900 | 2.9900 | 2.7700 |
| Apr 15, 2025 | 2.9150 | 0.1550 | 5.62% | 2.7600 | 2.9500 | 2.7150 |
| Apr 14, 2025 | 2.7650 | 0.2450 | 9.72% | 2.5200 | 2.8300 | 2.5200 |
| Apr 11, 2025 | 2.4350 | 0.0550 | 2.31% | 2.3800 | 2.5350 | 2.3400 |
| Apr 10, 2025 | 2.3500 | -0.1700 | -6.75% | 2.5200 | 2.5200 | 2.3500 |
| Apr 9, 2025 | 2.5700 | 0.0400 | 1.58% | 2.5300 | 2.7450 | 2.4200 |
| Apr 8, 2025 | 2.5200 | -0.2800 | -10.00% | 2.8000 | 2.8100 | 2.4900 |
| Apr 7, 2025 | 2.6650 | 0.0650 | 2.50% | 2.6000 | 2.8450 | 2.4900 |
| Apr 4, 2025 | 2.7100 | -0.0200 | -0.73% | 2.7300 | 2.7800 | 2.6000 |
| Apr 3, 2025 | 2.8450 | -0.0450 | -1.56% | 2.8900 | 2.9500 | 2.8400 |
| Apr 2, 2025 | 2.9850 | 0.0250 | 0.84% | 2.9600 | 3.0600 | 2.9100 |
| Apr 1, 2025 | 3.0300 | -0.0100 | -0.33% | 3.0400 | 3.0900 | 2.9200 |
| Mar 31, 2025 | 3.1000 | 0.0400 | 1.31% | 3.0600 | 3.1950 | 3.0600 |
| Mar 28, 2025 | 3.2650 | -0.1750 | -5.09% | 3.4400 | 3.4400 | 3.2450 |
| Mar 27, 2025 | 3.4250 | -0.0350 | -1.01% | 3.4600 | 3.5200 | 3.3400 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Cardiff Oncology, Inc. Company profile
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company''s onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.| Industry: | Biotechnology & Medical Research (NEC) |
11055 Flintkote Ave
SAN DIEGO
CALIFORNIA 92121
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com